After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols ...
Beginning June 1, 2020 all 5 CTS laboratories will being transitioning from the Grifols Procleix Ult...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
We sincerely hope to see you at this year’s AABB Annual Meeting in San Antonio, TX on October ...
As the US coast prepares for Hurricane Florence to make landfall, we have received importan...
Just a reminder that the revised client forms implement today! Don't forget to toss your o...